Masami Iwasa
Overview
Explore the profile of Masami Iwasa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Teramachi J, Tenshin H, Hiasa M, Oda A, Bat-Erdene A, Harada T, et al.
Haematologica
. 2020 Apr;
106(5):1401-1413.
PMID: 32273474
Along with the tumor progression, the bone marrow microenvironment is skewed in multiple myeloma (MM), which underlies the unique pathophysiology of MM and confers aggressiveness and drug resistance in MM...
2.
Iwasa M, Harada T, Oda A, Bat-Erdene A, Teramachi J, Tenshin H, et al.
Oncotarget
. 2019 Apr;
10(20):1903-1917.
PMID: 30956773
Immunotherapy is revolutionizing the treatment paradigm for multiple myeloma (MM). Interferon (IFN)-γ is essential for immune responses, whereas immune checkpoint molecules, such as programmed cell death-1 ligand-1 (PD-L1), mitigate the...
3.
Miki H, Nakamura S, Oura M, Hamano H, Ikuta K, Okada N, et al.
Br J Haematol
. 2019 Mar;
186(2):355-358.
PMID: 30859556
No abstract available.
4.
Bat-Erdene A, Nakamura S, Oda A, Iwasa M, Teramachi J, Ashtar M, et al.
Br J Haematol
. 2018 Nov;
185(5):969-974.
PMID: 30474853
No abstract available.
5.
Miki H, Nakamura S, Oda A, Tenshin H, Teramachi J, Hiasa M, et al.
Oncotarget
. 2018 Mar;
9(12):10307-10316.
PMID: 29535808
Multiple myeloma (MM) remains incurable, and MM-initiating cells or MM progenitors are considered to contribute to disease relapse through their drug-resistant nature. In order to improve the therapeutic efficacy for...
6.
Nakamura S, Azuma M, Maruhashi T, Sogabe K, Sumitani R, Uemura M, et al.
J Infect Chemother
. 2018 Feb;
24(5):389-392.
PMID: 29428565
Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne infectious disease caused by the SFTS virus (SFTSV). Clinical symptoms of SFTS often involve encephalopathy and other central neurological symptoms, particularly...
7.
Fujii S, Nakamura S, Oda A, Miki H, Tenshin H, Teramachi J, et al.
Br J Haematol
. 2018 Jan;
180(2):246-258.
PMID: 29327347
Proviral Integrations of Moloney virus 2 (PIM2) is overexpressed in multiple myeloma (MM) cells, and regarded as an important therapeutic target. Here, we aimed to validate the therapeutic efficacy of...
8.
Tenshin H, Teramachi J, Oda A, Amachi R, Hiasa M, Bat-Erdene A, et al.
Blood Adv
. 2018 Jan;
1(24):2124-2137.
PMID: 29296860
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) agonists induce tumor-specific apoptosis indicating that they may be an attractive therapeutic strategy against cancers, including multiple myeloma (MM). Osteoclastogenesis is highly induced in...
9.
Kagawa K, Fujino H, Miki H, Sogabe K, Takahashi M, Maruhashi T, et al.
Transpl Infect Dis
. 2017 Dec;
20(2):e12826.
PMID: 29277954
Disseminated Cryptosporidium infection results in manifestations similar to those of graft-versus-host disease (GVHD), which hampers the detection of Cryptosporidium infection after allogeneic hematopoietic stem cell transplantation. Surveillance of oocysts on...
10.
Kagawa K, Maeda Y, Oura M, Sogabe K, Fujino H, Takahashi M, et al.
Rinsho Ketsueki
. 2017 Dec;
58(11):2197-2204.
PMID: 29212969
Cardiac AL amyloidosis (CA) is generally known as a severe disease with very poor prognosis. Here we retrospectively examined seven patients with CA in our cohort who achieved long-term survival....